查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1945069

產品類型、患者年齡層、嚴重程度等級、通路和最終用戶分類的肥胖症診斷和治療市場-全球預測，2026-2032年

Obesity Diagnosis & Treatment Market by Product Category, Patient Age Group, Severity Class, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肥胖症診斷和治療市場價值將達到 132 億美元，到 2026 年將成長至 140.3 億美元，到 2032 年將達到 208.2 億美元，年複合成長率為 6.72%。

關鍵市場統計數據
基準年 2025 132億美元
預計年份：2026年 140.3億美元
預測年份 2032 208.2億美元
複合年成長率 (%) 6.72%

權威框架，闡述當前肥胖症診斷和治療格局，重點關注臨床、商業和醫療服務的關鍵轉折點。

肥胖症已從公共衛生挑戰演變為一個複雜的臨床和商業性領域，涉及診斷、治療和護理服務模式的交匯點。臨床醫生、支付方、醫療設備製造商、數位醫療創新者和生命科學公司如今身處一個快速變化的生態系統中，該生態系統受到新型藥物療法、先進治療技術和不斷擴展的遠距遠端醫療工具的影響。本導言概述了當前的環境，並整合了決策者關注的關鍵促進因素：臨床療效、報銷途徑、監管政策的清晰度、病人參與以及慢性病護理的經濟性。

臨床突破、日益成熟的數位技術和不斷演變的政策如何匯聚，從根本上重塑肥胖症治療路徑和市場競爭

由於技術、臨床和政策三大力量的融合，肥胖症的診斷和治療格局正在改變。這正在重新定義治療路徑和競爭格局。在臨床上，強效藥物療法的興起正在改變治療流程，並促使人們重新評估傳統的手術適應症標準。這些藥物為以前缺乏有效藥物治療的患者提供了更多選擇，從而改變了轉診模式和適合接受介入治療的患者群體。同時，醫療設備的創新，例如內視鏡袖狀胃切除術、胃內球囊和神經調控裝置，正在擴大微創手術的範圍，並創建結合手術和藥物治療的混合治療模式。

評估近期美國關稅變化如何影響肥胖治療產業中各相關人員的供應鏈、採購決策和成本管理

美國近期關稅調整和貿易政策變化對肥胖症診斷和治療產業的供應鏈決策和成本結構產生了重大影響。對於內視鏡袖套、胃內球囊和神經調控系統等醫療設備製造商而言，不斷變化的關稅政策迫使他們重新評估製造地和籌資策略，以維持利潤率。這些壓力促使他們採取短期營運應對措施，例如重新安排零件運輸路線、重新談判供應商契約，以及在某些情況下，將最終組裝業務遷址，以降低關稅風險。

綜合細分分析洞察，將產品類型、通路、臨床最終用戶、患者人口統計特徵和基於嚴重程度的治療路徑聯繫起來

細分市場分析揭示了透過產品類型、分銷管道、終端用戶畫像、患者年齡層和疾病嚴重程度分級來開拓市場時所面臨的明確機會和執行挑戰。按產品類型分類，數位健康解決方案包括行動應用程式、線上指導和遠端醫療服務，這些服務能夠實現可擴展的病人參與和遠端監測。同時，醫療設備提供內視鏡袖狀胃切除術、胃內球囊和神經調節裝置等選擇，為患者提供微創治療方案，以取代傳統手術。營養補充品涵蓋膳食纖維補充劑、草藥和蛋白質補充劑，可作為行為和藥物介入的輔助手段。藥物主要集中於Amylin類似物和GLP-1促效劑，這些藥物重新定義了藥物治療模式。外科手術包括可調式胃束帶術、膽胰分流術、胃繞道術和袖狀胃切除術，對於病情較重和合併特定疾病的患者仍然至關重要。

區域策略重點和市場進入差異會影響美洲、歐洲、中東和非洲以及亞太地區的採用和商業化。

區域趨勢差異顯著，對新參與企業和現有企業都產生了策略性影響。在美洲，醫療支付者和私人醫療機構正迅速採用藥物創新，同時在門診中心和醫院擴大外科手術能力，這得益於強大的臨床試驗網路和私營部門對數位醫療平台的積極投資。歐洲、中東和非洲地區（EMEA）環境複雜多樣，監管環境、報銷結構以及專業醫療設施的可近性在不同地區差異顯著。相關人員必須認真考慮不同的支付方環境和區域卓越中心，這些因素將影響外科手術和器械解決方案的地域滲透率。亞太地區的特點是都市化和生活方式改變推動了需求的快速成長，同時，對遠端醫療和可擴展的體重管理項目的投資也在不斷增加，這些項目能夠服務於龐大且多元化的人群。

競爭與合作並存的企業行為正在塑造製藥、醫療設備和數位領域的創新、證據產生和整合式醫療服務。

在肥胖症診斷和治療領域，主要企業的發展趨勢反映出強烈的創新精神、策略聯盟和產品組合多元化，各公司都在尋求利用藥物、醫療設備和數位化帶來的機會。領先的製藥創新者正優先進行強力的臨床項目和真實世界證據研究，以證明其藥物的長期代謝獲益和心血管安全性，這將有助於與支付方進行談判並最終納入藥品目錄。醫療設備製造商正投資於內視鏡和神經調控平台的迭代設計改進，以提高病患舒適度、縮短手術時間，並將應用範圍擴展到三級醫療中心以外的地區。他們通常與臨床專家合作，以加速產品推廣應用並完善治療通訊協定。

產業領導者可採取切實可行的策略重點，以加速技術應用、建立具有韌性的供應鏈，並產生符合支付方預期的證據。

產業領導者必須採取果斷行動，確保在優先考慮永續可及性和公平醫療服務的同時，掌握臨床相關性和商業性機會。首先，企業應透過進行縱向結果研究和真實世界證據項目，使臨床開發與支付方的證據需求保持一致，以證明持續的體重減輕、代謝改善和醫療資源利用方面的益處。這種方法將加強與支付方的談判，並支持基於價值的合約。其次，企業應推行整合產品策略，將藥物療法、器材選擇和數位化互動平台結合，建構端到端的醫療服務路徑。此類整合解決方案將提高患者的用藥依從性，並提供與單一療法競爭對手的有力競爭優勢。

一套穩健的多源調查方法，整合了臨床證據、相關人員訪談和供應鏈分析，以檢驗策略見解。

本分析的調查方法結合了系統性的證據綜合、專家訪談和跨部門檢驗，旨在得出反映臨床、商業性和政策現實的可操作性見解。此方法首先對同儕審查的臨床文獻、監管申報文件、指導文件和公共臨床試驗註冊庫進行系統性回顧，以確定藥物、手術創新和器械技術的臨床有效性和安全性。此外，也透過檢驗醫療系統指南、支付方政策聲明和報銷框架，進一步了解醫療服務取得和合約簽訂趨勢。

一項綜合分析強調，要使肥胖治療產生長期影響，需要整合證據、增強運作韌性並制定因地制宜的策略。

分析結論指出，肥胖症的診斷和治療生態系統正處於轉折點，其特徵是藥物學、器械干預和數位化醫療模式的融合創新。這些趨勢正在創建新的臨床路徑，拓展治療選擇，並促進臨床醫生、製造商和數位醫療服務提供者之間的跨學科合作。支付方和醫療系統越來越要求提供長期獲益和成本效益的證據，這使得製造商和服務提供者有責任提供嚴謹的療效數據和切實可行的交付模式。因此，那些將強大的循證能力、整合的醫療服務和穩健的營運策略相結合的機構將主導市場變革並維持市場佔有率。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依產品類型的肥胖症診斷與治療市場

  • 數位健康解決方案
    • 行動應用
    • 線上輔導
    • 遠端醫療服務
  • 醫療設備
    • 內視鏡袖狀胃成形術
    • 胃內球囊
    • 神經調控裝置
  • 營養補充品
    • 膳食纖維補充劑
    • 草藥補充劑
    • 蛋白質補充劑
  • 製藥
    • Amylin類似物
    • GLP-1促效劑
  • 外科手術
    • 可調式胃束帶
    • 膽胰分流術
    • 胃繞道手術
    • 袖狀切除術

9. 按患者年齡層分類的肥胖症診斷與治療市場

  • 成人版
  • 老年人
  • 兒童

第10章 依嚴重程度分類的肥胖症診斷與治療市場

  • 一級
  • 二類
  • 三級

第11章 按分銷管道分類的肥胖症診斷和治療市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專業診所頻道

第12章 依最終使用者分類的肥胖症診斷與治療市場

  • 門診手術中心
  • 診所
  • 家庭醫療保健
  • 醫院

第13章 各地區的肥胖診斷與治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的肥胖症診斷與治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國肥胖症診斷與治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國肥胖症診斷與治療市場

第17章 中國肥胖症診斷與治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Apollo Endosurgery, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • BTL Aesthetics
  • CH Boehringer Sohn AG & Ko. KG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gelesis, Inc.
  • GlaxoSmithKline plc
  • Herbalife Nutrition Ltd.
  • Johnson & Johnson Services, Inc.
  • Larimar Therapeutics, Inc.
  • Medifast, Inc.
  • Medtronic PLC
  • Novo Nordisk A/S
  • NutriSystem, Inc.
  • Olympus Corporation
  • Pfizer, Inc.
  • ReShape Lifesciences Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vivus, Inc.
Product Code: MRR-8D2A8050FA72

The Obesity Diagnosis & Treatment Market was valued at USD 13.20 billion in 2025 and is projected to grow to USD 14.03 billion in 2026, with a CAGR of 6.72%, reaching USD 20.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.20 billion
Estimated Year [2026] USD 14.03 billion
Forecast Year [2032] USD 20.82 billion
CAGR (%) 6.72%

An authoritative framing of the current obesity diagnosis and treatment landscape highlighting clinical, commercial, and care-delivery inflection points

Obesity has evolved from a public health challenge to a complex clinical and commercial landscape where diagnostics, therapeutics, and care delivery models intersect. Clinicians, payers, device manufacturers, digital health innovators, and life-science companies now operate within a fast-moving ecosystem shaped by novel pharmacotherapies, rising procedural sophistication, and an expanding array of remote care tools. This introduction frames the current environment by synthesizing drivers that matter to decision-makers: clinical efficacy, reimbursement pathways, regulatory clarity, patient engagement, and the economics of chronic care.

Across care settings, advances in pharmacology-most notably incretin-based agents-have catalyzed renewed attention to medical management, while emergent technologies in endoscopic and neuromodulation devices present alternatives or complements to surgical approaches. Simultaneously, digital health solutions including mobile applications, telehealth services, and online coaching are reshaping patient monitoring and adherence interventions, creating continuous touchpoints that extend beyond episodic encounters. These developments occur against a backdrop of increasing emphasis on integrated care pathways, where multidisciplinary teams and ambulatory centers play a larger role in delivering tailored interventions.

Policy shifts and payer interest in long-term outcomes reinforce a movement toward value-based care models that prioritize sustained weight reduction and comorbidity improvement rather than short-term metrics alone. In this context, stakeholders must weigh clinical innovation against access constraints and implementation complexity. The introduction sets the stage for deeper exploration of market dynamics, strategic inflection points, and pragmatic considerations for organizations seeking to navigate the rapidly changing obesity diagnosis and treatment environment.

How clinical breakthroughs, digital maturation, and policy evolution are converging to fundamentally reshape obesity care pathways and market competition

The landscape of obesity diagnosis and treatment is undergoing transformative shifts driven by converging technological, clinical, and policy forces that are redefining care pathways and competitive positioning. Clinically, the rise of potent pharmacotherapies has altered treatment algorithms and stimulated re-evaluation of traditional surgical thresholds; these agents are expanding options for patients who previously lacked viable medical alternatives, thereby changing referral patterns and the composition of candidates for invasive procedures. At the same time, device innovation in endoscopic sleeve techniques, intragastric balloons, and neuromodulation devices is broadening the spectrum of minimally invasive interventions, creating hybrid care models that blend procedural and medical management.

On the digital front, mobile applications, telehealth services, and online coaching platforms have matured from engagement-focused adjuncts into core components of chronic disease management, enabling continuous monitoring, remote titration of therapies, and improved adherence. This digital maturation facilitates earlier diagnosis through remote screening tools and enhances long-term follow-up. From a systems perspective, payers and health systems are increasingly focused on outcome-driven contracts, pressuring manufacturers and providers to demonstrate sustained weight reduction and comorbidity improvements rather than short-term gains. Regulatory environments are also adapting, with faster review pathways and clearer guidance around novel combination approaches, which reduces time-to-market but raises the bar for robust lifecycle evidence.

Collectively, these shifts compel stakeholders to adopt integrated strategies that align product development, clinical evidence generation, and reimbursement planning. Organizations that invest in cross-functional capabilities-combining digital engagement, robust real-world evidence programs, and adaptive commercialization models-will be better positioned to capitalize on the sector's dynamic transformation.

Assessment of how recent United States tariff changes are reshaping supply chains, sourcing decisions, and cost management across obesity treatment stakeholders

Recent tariff adjustments and trade policy developments in the United States have materially influenced supply chain decisions and cost structures across the obesity diagnosis and treatment landscape. For manufacturers of medical devices such as endoscopic sleeves, intragastric balloons, and neuromodulation systems, shifting tariff schedules have necessitated reevaluation of manufacturing footprints and sourcing strategies to protect margin integrity. These pressures prompt near-term operational responses including re-routing of components, renegotiation of supplier contracts, and, in select cases, relocation of final assembly to mitigate tariff exposure.

Pharmaceutical supply chains have also felt the impact, particularly where active pharmaceutical ingredients or finished products move across borders. Organizations have increased emphasis on supply diversification, multi-sourcing, and strategic stockpiling to avoid disruption to therapeutic availability. For digital health companies and software-centric solutions, the tariff impact is comparatively indirect but still relevant where hardware peripherals or integrated devices are sourced internationally. Distribution channels have responded by reassessing landed costs and adjusting pricing strategies for hospital pharmacies, retail outlets, online pharmacies, and specialty clinics to maintain competitiveness while preserving access.

In response, stakeholders must balance cost mitigation with continuity of care. Health systems and payers are likely to scrutinize cost-pass-throughs and seek contractual protections in supplier agreements. Longer term, tariffs may accelerate onshoring or nearshoring initiatives for critical components, while increasing collaboration between manufacturers and distributors to maintain stable supply. The net effect is a market environment where strategic supply chain resilience becomes a core competency for organizations operating in obesity diagnosis and treatment.

Comprehensive segmentation-driven insights linking product types, distribution pathways, clinical end users, patient demographics, and severity-driven care pathways

Segmentation analysis reveals distinct opportunities and execution challenges when viewing the market through product categories, distribution channels, end-user profiles, patient age groups, and severity classes. When organized by product category, digital health solutions encompass mobile applications, online coaching, and telehealth services that enable scalable patient engagement and remote monitoring, while medical devices include endoscopic sleeve, intragastric balloon, and neuromodulation device options that provide minimally invasive procedural alternatives to traditional surgery. Nutritional supplements span fiber supplements, herbal supplements, and protein supplements that serve as adjuncts to behavioral and medical interventions. Pharmaceuticals are concentrated in amylin analogues and GLP-1 agonists that have redefined pharmacologic treatment paradigms. Surgical procedures include adjustable gastric banding, biliopancreatic diversion, gastric bypass, and sleeve gastrectomy that remain essential for patients with advanced severity or specific comorbidity profiles.

Looking across distribution channels, hospital pharmacy, online pharmacy, retail pharmacy, and specialty clinic channels each present unique access and reimbursement dynamics that influence formulary placement, uptake speed, and patient convenience. End users such as ambulatory surgical centers, clinics, home healthcare providers, and hospitals differ in procedural capabilities, staffing models, and capital requirements, which in turn affects where particular interventions are most effectively deployed. Patient age group segmentation-adult, geriatric, and pediatric-necessitates tailored clinical approaches, dosing strategies, and patient engagement techniques, with pediatrics requiring additional focus on family-centered care and long-term behavioral supports. Severity class segmentation across Class I, Class II, and Class III obesity demands calibrated clinical pathways; for example, moderate cases may benefit most from pharmacotherapy combined with digital coaching, whereas advanced cases often require multidisciplinary evaluation and procedural options. Integrating these segmentation lenses allows stakeholders to refine product positioning, prioritize channels for commercial outreach, and design evidence generation programs that align with the specific needs of each subpopulation.

Regional strategic imperatives and market access variations across the Americas, Europe Middle East & Africa, and Asia-Pacific that affect adoption and commercialization

Regional dynamics vary significantly and shape strategic imperatives for market entrants and incumbents alike. In the Americas, healthcare payers and commercial providers have rapidly adopted pharmacologic innovations alongside expanded procedural capacity in ambulatory centers and hospitals, supported by strong clinical trial networks and active private sector investment in digital health platforms. Europe, Middle East & Africa presents a heterogeneous environment where regulatory frameworks, reimbursement systems, and access to specialized centers vary widely; stakeholders must navigate diverse payer landscapes and regional centers of excellence that influence where surgical and device-based solutions gain traction. Asia-Pacific is characterized by rapidly growing demand driven by urbanization and changing lifestyle patterns, concurrent with expanding investments in telehealth and scalable weight management programs that can address large, diverse populations.

Each region's distribution infrastructure and channel preferences differ, with hospital and specialty clinic channels dominating in settings where procedural capacity is concentrated, while online pharmacies and telehealth-led services proliferate where digital adoption and regulatory allowances enable remote care. Cross-border regulatory harmonization and partnerships with local clinical networks are critical enablers in Europe, Middle East & Africa and parts of Asia-Pacific, whereas the Americas often emphasize outcomes-based contracting and private payer negotiations. These regional distinctions necessitate tailored market entry strategies, localized evidence generation, and partnerships that align with regional reimbursement policies and clinical referral patterns. Consequently, firms should align commercialization tactics with the specific regulatory, payer, and care-delivery realities of each macro region to accelerate adoption and ensure sustained patient access.

Competitive and collaborative company behaviors shaping innovation, evidence generation, and integrated care offers across pharmacologic, device, and digital players

Key company dynamics in obesity diagnosis and treatment reflect intense innovation, strategic collaborations, and portfolio diversification as firms seek to capture opportunities across pharmacologic, device, and digital domains. Leading pharmaceutical innovators have prioritized robust clinical programs and real-world evidence initiatives to demonstrate long-term metabolic benefits and cardiovascular safety, which supports payer negotiations and formulary inclusion. Device manufacturers are investing in iterative design improvements for endoscopic and neuromodulation platforms to enhance patient comfort, reduce procedural time, and broaden applicability beyond tertiary centers, often collaborating with clinical leaders to accelerate adoption and refine procedural protocols.

Digital health companies are increasingly forming partnerships with pharmaceutical and device firms to create integrated care pathways that combine pharmacotherapy, remote monitoring, and behavioral coaching, thereby strengthening adherence and outcomes. Meanwhile, distributors and specialty clinics are evolving their service offerings to incorporate bundled care delivery models that combine diagnostics, therapy initiation, and follow-up, improving patient retention and value demonstration. Across these movements, mid-size innovators and niche players play an important role by converging targeted technologies-such as adjunct nutritional supplements or focused telehealth solutions-into broader care ecosystems. Competitive differentiation increasingly stems from the ability to generate comprehensive evidence packages, demonstrate interoperability with electronic health records and remote monitoring tools, and negotiate innovative reimbursement arrangements that align incentives between manufacturers, providers, and payers.

Actionable strategic priorities for industry leaders to accelerate adoption, build resilient supply chains, and align evidence generation with payer expectations

Industry leaders must act decisively to capture clinical relevance and commercial opportunity while prioritizing sustainable access and equitable care. First, organizations should align clinical development with payer evidence needs by building long-term outcome studies and real-world evidence programs that demonstrate durable weight reduction, metabolic improvement, and healthcare utilization benefits. This approach strengthens negotiations with payers and supports value-based contracting. Second, companies should pursue integrated product strategies that combine pharmacologic therapies, device options, and digital engagement platforms to create end-to-end care pathways; such integrated offerings improve adherence and create defensible differentiation against single-modality competitors.

Third, investing in supply chain resilience and flexible manufacturing footprints mitigates tariff and trade risks, while strategic partnerships with regional distributors and specialty clinics optimize market access. Fourth, leaders should prioritize interoperability and data-sharing capabilities to ensure digital tools and monitoring systems integrate seamlessly into provider workflows and electronic health records, enabling scalable care coordination. Fifth, organizations must refine segmentation strategies to target interventions by patient age and severity class, tailoring clinical trial designs and commercial messaging to the needs of adult, geriatric, and pediatric populations as well as Class I through Class III severity strata. Finally, proactive engagement with regulators and payers to clarify evidence requirements and reimbursement models will accelerate adoption. Together, these actions form a pragmatic roadmap for industry leaders to translate innovation into sustained clinical and commercial impact.

Robust multi-source research methodology integrating clinical evidence, stakeholder interviews, and supply chain analysis to validate strategic insights

The research methodology underpinning this analysis combined systematic evidence synthesis, expert interviews, and cross-functional triangulation to produce actionable insights that reflect clinical, commercial, and policy realities. The approach began with a structured review of peer-reviewed clinical literature, regulatory filings, guidance documents, and publicly available clinical trial registries to establish the clinical efficacy and safety profiles of pharmacologic agents, procedural innovations, and device technologies. This literature foundation was augmented by an examination of health system guidance, payer policy statements, and reimbursement frameworks to understand access dynamics and contractual trends.

To contextualize these findings, the research incorporated primary qualitative inputs from clinicians, hospital administrators, device developers, digital health executives, and payer representatives to validate hypotheses and surface implementation barriers. These expert engagements informed assessments of adoption drivers, channel dynamics, and regional nuances. The analysis also examined supply chain structures and tariff impacts by reviewing import data, supplier footprint strategies, and public trade policy disclosures to evaluate operational risks. Finally, insights were synthesized through cross-validation between clinical evidence and market practice, emphasizing pragmatic implications for stakeholders. This multi-source and multi-stakeholder methodology ensures that the conclusions are grounded in both empirical evidence and operational realities, supporting confident strategic decision-making.

Concluding synthesis underscoring the need for integrated evidence, operational resilience, and regionally tailored strategies to realize long-term impact in obesity care

This analysis concludes that the obesity diagnosis and treatment ecosystem is at an inflection point defined by convergent innovations in pharmacology, device-based interventions, and digital care models. These trends create new clinical pathways that expand therapeutic options and invite cross-disciplinary collaboration among clinicians, manufacturers, and digital health providers. Payers and health systems increasingly demand evidence of long-term benefit and cost-effectiveness, which shifts the burden to manufacturers and providers to supply rigorous outcome data and practical delivery models. Consequently, the organizations that combine strong evidence-generation capabilities with integrated care offerings and resilient operational strategies will lead adoption and sustain market relevance.

At the same time, supply chain and trade considerations underscore the importance of operational agility; proactive supply diversification and regional partnerships will be essential to protect access. Segmentation analysis highlights the need for tailored strategies across product types, channels, end users, patient age groups, and severity classes, enabling more precise targeting of clinical programs and commercial investments. Regional variability further emphasizes that a one-size-fits-all approach will underperform; instead, market entry and expansion must be adapted to local regulatory, reimbursement, and care-delivery contexts. In sum, the path forward requires coordinated action across clinical development, commercial execution, and payer engagement to convert innovation into sustained patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Obesity Diagnosis & Treatment Market, by Product Category

  • 8.1. Digital Health Solutions
    • 8.1.1. Mobile Applications
    • 8.1.2. Online Coaching
    • 8.1.3. Telehealth Services
  • 8.2. Medical Devices
    • 8.2.1. Endoscopic Sleeve
    • 8.2.2. Intragastric Balloon
    • 8.2.3. Neuromodulation Device
  • 8.3. Nutritional Supplements
    • 8.3.1. Fiber Supplements
    • 8.3.2. Herbal Supplements
    • 8.3.3. Protein Supplements
  • 8.4. Pharmaceuticals
    • 8.4.1. Amylin Analogues
    • 8.4.2. Glp-1 Agonists
  • 8.5. Surgical Procedures
    • 8.5.1. Adjustable Gastric Banding
    • 8.5.2. Biliopancreatic Diversion
    • 8.5.3. Gastric Bypass
    • 8.5.4. Sleeve Gastrectomy

9. Obesity Diagnosis & Treatment Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Obesity Diagnosis & Treatment Market, by Severity Class

  • 10.1. Class I
  • 10.2. Class II
  • 10.3. Class III

11. Obesity Diagnosis & Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
  • 11.4. Specialty Clinic Channels

12. Obesity Diagnosis & Treatment Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Home Healthcare
  • 12.4. Hospitals

13. Obesity Diagnosis & Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Obesity Diagnosis & Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Obesity Diagnosis & Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Obesity Diagnosis & Treatment Market

17. China Obesity Diagnosis & Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Amgen Inc.
  • 18.8. Apollo Endosurgery, Inc.
  • 18.9. AstraZeneca PLC
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. BTL Aesthetics
  • 18.12. C.H. Boehringer Sohn AG & Ko. KG
  • 18.13. Eli Lilly and Company
  • 18.14. F. Hoffmann-La Roche Ltd.
  • 18.15. Gelesis, Inc.
  • 18.16. GlaxoSmithKline plc
  • 18.17. Herbalife Nutrition Ltd.
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Larimar Therapeutics, Inc.
  • 18.20. Medifast, Inc.
  • 18.21. Medtronic PLC
  • 18.22. Novo Nordisk A/S
  • 18.23. NutriSystem, Inc.
  • 18.24. Olympus Corporation
  • 18.25. Pfizer, Inc.
  • 18.26. ReShape Lifesciences Inc.
  • 18.27. Sanofi S.A.
  • 18.28. Takeda Pharmaceutical Company Limited
  • 18.29. Vivus, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE COACHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE COACHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE COACHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TELEHEALTH SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TELEHEALTH SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TELEHEALTH SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FIBER SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FIBER SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FIBER SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HERBAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HERBAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HERBAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PROTEIN SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PROTEIN SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PROTEIN SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMYLIN ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMYLIN ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMYLIN ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BILIOPANCREATIC DIVERSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BILIOPANCREATIC DIVERSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BILIOPANCREATIC DIVERSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SLEEVE GASTRECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SLEEVE GASTRECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SLEEVE GASTRECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINIC CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINIC CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINIC CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 222. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 251. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 252. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 254. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 255. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 261. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 262. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 263. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 266. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)